VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CAMPBELL, Calif. , April 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per
View HTML
Toggle Summary VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
CAMPBELL, Calif. , April 01, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the
View HTML
Toggle Summary VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19 CAMPBELL, Calif. , March 31, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results
- Company to host conference call today at 4:30pm ET - CAMPBELL, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported financial results for the quarter and fiscal year ended December 31, 2019 and provided a business
View HTML
Toggle Summary VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents
-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need- CAMPBELL, Calif. , March 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced
View HTML
Toggle Summary VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
- VIVUS to Receive Milestone Payment from Alvogen ; Significant Worldwide Growth Potential for Qsymia - CAMPBELL, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen , has
View HTML
Toggle Summary VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
CAMPBELL, Calif. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019 after the market close on Tuesday, March 3, 2020 . The company will host a conference call with
View HTML
Toggle Summary VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life
CAMPBELL, Calif. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE ®
View HTML
Toggle Summary New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia- CAMPBELL, Calif. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc.
View HTML
Toggle Summary VIVUS to Present at Biotech Showcase on January 13, 2020
CAMPBELL, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos , Chief Executive Officer, will present at the Biotech Showcase™ 2020 on Monday, January 13, 2020 at 3:30 pm PT / 6:30pm ET .
View HTML